Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for China Pharma Holdings (CPHI) over the last 16 years, with Q3 2025 value amounting to -$122214.0.

  • China Pharma Holdings' Cash from Financing Activities fell 188597.11% to -$122214.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$214633.0, marking a year-over-year decrease of 52143.57%. This contributed to the annual value of $27353.0 for FY2024, which is 6260.44% down from last year.
  • Per China Pharma Holdings' latest filing, its Cash from Financing Activities stood at -$122214.0 for Q3 2025, which was down 188597.11% from -$29188.0 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Cash from Financing Activities peaked at $4.6 million during Q4 2021, and registered a low of -$850555.0 during Q2 2022.
  • Moreover, its 5-year median value for Cash from Financing Activities was $934.0 (2023), whereas its average is $142462.8.
  • Per our database at Business Quant, China Pharma Holdings' Cash from Financing Activities soared by 4592852.89% in 2021 and then plummeted by 188597.11% in 2025.
  • Over the past 5 years, China Pharma Holdings' Cash from Financing Activities (Quarter) stood at $4.6 million in 2021, then crashed by 114.55% to -$672063.0 in 2022, then soared by 104.52% to $30378.0 in 2023, then crashed by 77.61% to $6802.0 in 2024, then plummeted by 1896.74% to -$122214.0 in 2025.
  • Its Cash from Financing Activities stands at -$122214.0 for Q3 2025, versus -$29188.0 for Q2 2025 and -$70033.0 for Q1 2025.